Mednet Logo
CommunityOphthalmology

When would you offer neoadjuvant immunotherapy prior to Mohs surgery in a locally advanced squamous cell carcinoma for which clearance may require enucleation?

3 Answers
Mednet Member
Mednet MemberInvited Expert
Radiation Oncology · UT Southwestern School of Medicine
Answered on

I would flip this question around and answer that radiotherapy is often a terrific option around the eyes, and it should always be considered in this area, especially when a radical surgical procedure is being entertained.

Between en face therapy with a shield (superficial, electrons) and IMRT/VMAT,...

Join for free or sign in to see the full answer

Mednet Member
Mednet MemberInvited Expert
Dermatology · Florida State University College of Medicine
Answered on

The potential loss of an eye involves major decision-making and pre-planning with a team. I remember as a fellow working with @Dr. First Last at The Eye Foundation Hospital Foundation in Birmingham, hospital bylaws required the surgeon to wake a patient and get permission if a Mohs case got to the p...

Join for free or sign in to see the full answer

Mednet Member
Mednet MemberInvited Expert
Medical Oncology · The Ohio State University Comprehensive Cancer Center
Answered on

Since the question is about immunotherapy, my answer is yes. I would start on cemiplimab neoadjuvant for at least 2 cycles, but I prefer 4 cycles prior to surgery to deepen the response. Many patients will not need surgery afterwards, as the cemiplimab can cure a significant percentage of these pati...

Join for free or sign in to see the full answer